Page 154 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

146. Wilt TJ, Brawer MK, Barry MJ, et al. The 155. Mohler JL, Williams BT, Freeman JA.
Prostate cancer Intervention Versus
Observation Trial:VA/NCI/AHRQ
Cooperative Studies Program #407
(PIVOT): design and baseline results of a
randomized controlled trial comparing
radical prostatectomy to watchful waiting 156.
for men with clinically localized prostate
cancer. Contemp Clin Trials 2009;30:81-87.
147. Stratton MS, Reid ME, Schwartzberg G, et
al. Selenium and inhibition of disease 157.
progression in men diagnosed with prostate
carcinoma: study design and baseline
characteristics of the 'Watchful Waiting'
Study. Anticancer Drugs 2003;14:595-600.
148. McIntyre IG, Clarke RB, Anderson E, et al. .
Molecular prediction of progression in 158.
patients with conservatively managed
prostate cancer. Urology 2001;58:762-766.
159.
149. Anai S, Nakamura K, Chang MN, et al. The
feasibility of expectant management with
inner-city men with newly diagnosed
localized prostate cancer. J Health Care Poor
Underserved 2008;19:164-170.
150. Roemeling S, Roobol MJ, de Vries SH, et al. 160.
Active surveillance for prostate cancers
detected in three subsequent rounds of a
screening trial: characteristics, PSA
doubling times, and outcome. Eur Urol
2007;51:1244-1250. 161.
151. van den Bergh RC, Roemeling S, Roobol
MJ, et al. Outcomes of men with screen-
detected prostate cancer eligible for active
surveillance who were managed expectantly.
Eur Urol 2009;55:1-8.
162.
152. Tilling K, Garmo H, Metcalfe C, et al.
Development of a new method for
monitoring prostate-specific antigen changes
in men with localised prostate cancer: a
comparison of observational cohorts. Eur
Urol 2010;57:446-452. 163.
153. Kakehi Y, Kamoto T, Ogawa O, et al.
Clinical significance of nonpalpable prostate
cancer with favorable biopsy features in
Japanese men. Eur Urol 2000;37:552-558.
164.
154. Arai Y, Egawa S, Kuwao S, et al. The role
of volume-weighted mean nuclear volume in
predicting tumour biology and clinical
behaviour in patients with prostate cancer
undergoing watchful waiting. BJU Int
2001;88:909-914.
100
Expectant management as an option for men
with stage T1c prostate cancer: a
preliminary study. World J Urol
1997;15:364-368.
Finelli A, Trottier G, Lawrentschuk N, et al.
Impact of 5alpha-reductase inhibitors on
men followed by active surveillance for
prostate cancer. Eur Urol 2011;59:509-514.
McLaren DB, McKenzie M, Duncan G, et
al. Watchful waiting or watchful
progression?: Prostate specific antigen
doubling times and clinical behavior in
patients with early untreated prostate
carcinoma. Cancer 1998;82:342-348.
Lee EK, Baack J, Penn H, et al. Active
surveillance for prostate cancer in a veteran
population. Can J Urol 2010;17:5429-5435.
Snyder CF, Frick KD, Blackford AL, et al.
How does initial treatment choice affect
short-term and long-term costs for clinically
localized prostate cancer? Cancer
2010;116:5391-5399.
Dall’era MA, Hosang N, Konety B, et al.
Sociodemographic predictors of prostate
cancer risk category at diagnosis: unique
patterns of significant and insignificant
disease. J Urol 2009;181:1622-1627.
Barocas DA, Cowan JE, Smith Jr JA, et al.
What percentage of patients with newly
diagnosed carcinoma of the prostate are
candidates for surveillance? An analysis of
the CaPSURE database. J Urol
2008;180:1330-1334.
Konety BR, Cowan JE, Carroll PR. Patterns
of primary and secondary therapy for
prostate cancer in elderly men: analysis of
data from CaPSURE. J Urol 2008;179:1797-
1803.
Sadetsky N, Elkin EP, Latini DM, et al.
Prostate cancer outcomes among older men:
insurance status comparisons results from
CaPSURE database. Prostate Cancer
Prostatic Dis 2008;11:280-287.
Latini DM, Hart SL, Knight SJ, et al. The
relationship between anxiety and time to
treatment for patients with prostate cancer
on surveillance. J Urol 2007;178:826-831.